Anika Appoints Robert Richard, Ph.D. as Vice President of Research and Development
March 18 2019 - 8:30AM
Business Wire
Industry veteran brings extensive experience
leading high-performing R&D groups
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced the appointment of Robert Richard,
Ph.D., to the newly created position of Vice President of Research
and Development. Dr. Richard is a 20-year research and development
(R&D) veteran bringing extensive leadership and product
development experience in orthopedic and regenerative medicine. In
this new role, Dr. Richard will oversee the Company’s global
R&D function and the development of the Company’s novel product
offerings from concept through commercialization.
“We are delighted to strengthen our R&D expertise and our
executive leadership team with the addition of Dr. Richard, as we
continue Anika’s ongoing transformation into a global commercial
organization,” said Joseph Darling, President and Chief Executive
Officer of Anika Therapeutics. “His depth of knowledge and
experience will help us to accelerate and advance our orthopedic
and regenerative medicine pipeline and leverage the broad utility
of our technology platform.”
“I am excited to lead Anika’s R&D function during its next
phase of innovative growth,” said Robert Richard, Ph.D., Vice
President of Research and Development at Anika Therapeutics. “Anika
has the resources to deliver a cascade of innovative treatments to
patients over the next several years and I look forward to working
with this talented R&D organization and management team.”
Dr. Richard has previously held leadership positions with C.R.
Bard, Boston Scientific, and Johnson & Johnson, where he led
R&D organizations through numerous product development
initiatives from the conceptual phase through commercialization.
While leading R&D at the surgical division at C.R. Bard, Dr.
Richard led programs that launched over 20 new products based on
advanced biomaterials technologies over a ten-year period.
Most recently, he led the R&D organization at Hyalex
Orthopaedics, an early-stage medical device company advancing
treatments based on a novel polymer technology that mimics
cartilage. He holds a Ph.D. in polymer chemistry and plastics
engineering from the University of Massachusetts Lowell as well as
bachelor of science degrees in chemistry and biology from the
University of Massachusetts Dartmouth. Dr. Richard is a named
inventor on 38 U.S. patents and currently has 19 U.S. patent
applications pending. Click here to view Dr. Richard’s full
bio.
About Anika Therapeutics, Inc.Anika Therapeutics,
Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and
regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic
conditions with clinically meaningful therapies along the continuum
of care, from palliative pain management to regenerative tissue
repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration. For more information about
Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190318005073/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial Officer
For Media Inquiries:W2O GroupSonal Vasudev,
917-523-1418sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024